No more reading glasses? New FDA-approved eye drops can fix your near vision
Known as Vizz, manufactured by pharmaceutical company Lenz, the once-daily drops treat age-related blurry near vision — also known as presbyopia — for up to 10 hours at a time.
While it's not a permanent solution, users may not have to consistently keep reading glasses nearby or put in contact lenses every day.
Presbyopia is a common condition found in many people, particularly those over the age of 40, who begin to have difficulty reading words up close as their vision begins to deteriorate with age. Often, they will begin using reading glasses or contact lenses, holding books, phones and other small print farther away, or even increasing the light and font on their screens to see more clearly.
Story continues below advertisement
According to the manufacturer, Vizz works with the help of a chemical called aceclidine, which creates a 'pinhole effect' in the eye, narrowing the pupil in a way similar to a camera lens, which brings close-up objects and text into clearer focus.
Unlike previously released eye drops that also help reduce presbyopia by affecting the focusing muscles of the eye, Vizz won't cause a 'zoomed-in' effect or blur distance vision, the company says.
Get weekly health news
Receive the latest medical news and health information delivered to you every Sunday. Sign up for weekly health newsletter Sign Up
By providing your email address, you have read and agree to Global News' Terms and Conditions and Privacy Policy
Plus, it claims their newly approved drops don't cause adverse side effects like brow heaviness due to ciliary muscle activation.
That's not to say Vizz eye drops don't come with any side effects. The FDA guidance says users 'may experience temporary dim or dark vision after instillation,' and warns against driving or operating heavy machinery with blurred vision. There's also a warning to exercise caution while driving at night or participating in other activities in low light.
Story continues below advertisement
There have also been rare cases of retinal tears and detachments when using miotics, especially in those with pre-existing retinal disease.
A certain percentage of patients who used the drug during clinical trials experienced eye irritation (20 per cent) and headache (13 per cent).
'This FDA approval represents a disruptive paradigm shift in treatment options for millions of people who are frustrated and struggling with the inevitable age-related loss of their near vision,' said Vizz clinical investigator Marc Bloomenstein, from Schwartz Laser Eye Care Center in Scottsdale, Ariz., in a statement.
'I believe this will be a welcome solution for both optometrists and ophthalmologists who will now be able to offer a highly effective and sought-after presbyopia treatment that could immediately become the standard of care, with a product profile that will meet our patients' needs.'
Global News has reached out to Health Canada to ask whether the agency was looking to approve Vizz for Canadians, but did not hear back as of press time.
A report from Eyes on Eyecare released earlier this summer says that Lenz Therapeutics announced an exclusive licence and commercialization agreement with Théa — a European pharmaceutical company specializing in the research, development and commercialization of ophthalmic products — to help bring Vizz to Canada. So far, they say, no timeline has been established.
Story continues below advertisement
The drug is expected to be broadly available in the U.S. by October of this year.
The Canadian Association of Optometrists calls presbyopia a 'natural consequence of aging' that becomes noticeable as the eye loses elasticity and flexibility, usually first presenting between the ages of 40 and 45. It typically progresses until the late 40s or early 50s.
Statistics collected by Eye Health Central estimate that approximately 1.8 billion people are living with the condition, with data showing it's more common in North America; however, better access to eye exams in Canada and the United States could be driving the numbers up.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Global News
2 days ago
- Global News
No more reading glasses? New FDA-approved eye drops can fix your near vision
A new prescription eye drop that could potentially allow many people to put down their reading glasses has been approved by the U.S. Food and Drug Administration (FDA). Known as Vizz, manufactured by pharmaceutical company Lenz, the once-daily drops treat age-related blurry near vision — also known as presbyopia — for up to 10 hours at a time. While it's not a permanent solution, users may not have to consistently keep reading glasses nearby or put in contact lenses every day. Presbyopia is a common condition found in many people, particularly those over the age of 40, who begin to have difficulty reading words up close as their vision begins to deteriorate with age. Often, they will begin using reading glasses or contact lenses, holding books, phones and other small print farther away, or even increasing the light and font on their screens to see more clearly. Story continues below advertisement According to the manufacturer, Vizz works with the help of a chemical called aceclidine, which creates a 'pinhole effect' in the eye, narrowing the pupil in a way similar to a camera lens, which brings close-up objects and text into clearer focus. Unlike previously released eye drops that also help reduce presbyopia by affecting the focusing muscles of the eye, Vizz won't cause a 'zoomed-in' effect or blur distance vision, the company says. Get weekly health news Receive the latest medical news and health information delivered to you every Sunday. Sign up for weekly health newsletter Sign Up By providing your email address, you have read and agree to Global News' Terms and Conditions and Privacy Policy Plus, it claims their newly approved drops don't cause adverse side effects like brow heaviness due to ciliary muscle activation. That's not to say Vizz eye drops don't come with any side effects. The FDA guidance says users 'may experience temporary dim or dark vision after instillation,' and warns against driving or operating heavy machinery with blurred vision. There's also a warning to exercise caution while driving at night or participating in other activities in low light. Story continues below advertisement There have also been rare cases of retinal tears and detachments when using miotics, especially in those with pre-existing retinal disease. A certain percentage of patients who used the drug during clinical trials experienced eye irritation (20 per cent) and headache (13 per cent). 'This FDA approval represents a disruptive paradigm shift in treatment options for millions of people who are frustrated and struggling with the inevitable age-related loss of their near vision,' said Vizz clinical investigator Marc Bloomenstein, from Schwartz Laser Eye Care Center in Scottsdale, Ariz., in a statement. 'I believe this will be a welcome solution for both optometrists and ophthalmologists who will now be able to offer a highly effective and sought-after presbyopia treatment that could immediately become the standard of care, with a product profile that will meet our patients' needs.' Global News has reached out to Health Canada to ask whether the agency was looking to approve Vizz for Canadians, but did not hear back as of press time. A report from Eyes on Eyecare released earlier this summer says that Lenz Therapeutics announced an exclusive licence and commercialization agreement with Théa — a European pharmaceutical company specializing in the research, development and commercialization of ophthalmic products — to help bring Vizz to Canada. So far, they say, no timeline has been established. Story continues below advertisement The drug is expected to be broadly available in the U.S. by October of this year. The Canadian Association of Optometrists calls presbyopia a 'natural consequence of aging' that becomes noticeable as the eye loses elasticity and flexibility, usually first presenting between the ages of 40 and 45. It typically progresses until the late 40s or early 50s. Statistics collected by Eye Health Central estimate that approximately 1.8 billion people are living with the condition, with data showing it's more common in North America; however, better access to eye exams in Canada and the United States could be driving the numbers up.
National Post
3 days ago
- National Post
NFLPA confirms to players that the use of smelling salts is not banned
The NFL Players Association confirmed to players Wednesday that the NFL's new policy on smelling salts only prohibits teams from providing them to players on game days. The measure does not ban players from using them, the union clarified. Article content 'The NFL Players Association is aware of the memo issued by the league Tuesday regarding the use of smelling salts and ammonia capsules,' the NFLPA wrote in its memo, a copy of which was obtained by The Washington Post. 'We were not notified of this club policy change before the memo was sent out. To clarify, this policy does not prohibit player use of these substances, but rather it restricts clubs from providing or supplying them in any form. The NFL has confirmed this to us. If you have any questions, please reach out to your player director.' Article content Article content Article content The NFL informed teams Tuesday that they are prohibited from supplying ammonia capsules or any form of smelling salts to players on game days. However, a ban on use by players would have to be negotiated with the union. Article content The league's memo to teams, a copy of which The Post obtained Tuesday, noted that last year the Food and Drug Administration 'issued a warning to companies that produce commercially available ammonia inhalants (AIs), as well as to consumers about the purchase and use of AIs, regarding the lack of evidence supporting the safety or efficacy of AIs marketed for improving mental alertness or boosting energy. The FDA noted potential negative effects from AI use. AIs also have the potential to mask certain neurologic signs and symptoms, including some potential signs of concussion.' Article content That FDA warning led the NFL's head, neck and spine committee to recommend a prohibition on the use of ammonia inhalants 'for any purpose during play in the NFL,' according to the memo. Article content Article content 'In light of this information, effective for the 2025 NFL season, clubs are prohibited from providing or supplying ammonia in any form at NFL games,' the league said. 'For clarity, 'ammonia' refers to ammonia capsules, inhalers, ammonia in a cup, and any form of 'smelling salts.'' Article content The NFL told teams that the prohibition 'applies to all club personnel (including but not limited to team physicians, athletic trainers, strength and conditioning coaches and coaches or other personnel)' and will be in effect 'through the entirety of all NFL games, including during all pregame activities, and halftime, and applies on the sideline and in stadium locker rooms.' Article content San Francisco 49ers tight end George Kittle walked onto the NFL Network set at the team's training camp Tuesday to 'air a grievance,' he said. Article content 'Our team got a memo today that smelling salts and ammonia packets were made illegal in the NFL,' Kittle said, adding that he uses them on every offensive drive, 'and I've been distraught all day. … I considered retirement. … So we've got to figure out a middle ground here, guys. Somebody help me out. Somebody come up with a good idea.'
National Post
3 days ago
- National Post
ProteinQure Receives Regulatory Clearance to Initiate Phase I Trial for PQ203 in the U.S. and Canada; Granted FDA Fast Track Designation
Article content Article content TORONTO — ProteinQure, a leader in computational protein drug discovery, today announced it has received regulatory clearance from both the U.S. Food and Drug Administration (FDA) and Health Canada to initiate a Phase I clinical trial evaluating the safety, pharmacokinetics, pharmacodynamics and anti-cancer activity of its lead candidate, PQ203. The FDA has also granted PQ203 Fast Track designation for patients with triple negative breast cancer, recognizing the therapy's potential to address a serious unmet medical need. Article content The upcoming Phase I trial, which will be conducted in both the United States and Canada, will use an accelerated titration design to more efficiently identify the optimal dosing regimen while quickly arriving at therapeutic dose levels. Article content 'This is a major step forward for ProteinQure and for the field of rationally designed peptide therapeutics,' Article content said Dave Garman, VP Translation and Development at ProteinQure. Article content 'The Fast Track designation reflects the FDA's recognition of the promise PQ203 holds for cancer patients, and we are thrilled to move swiftly into the clinic across North America.' Article content PQ203 is a first-in-class therapeutic developed using ProteinQure's proprietary platform that integrates physics-based modeling with generative machine learning. The company believes PQ203 could unlock new frontiers in oncology by combining high specificity with novel mechanisms of action. Article content The Phase I study is expected to begin at Princess Margaret Cancer Centre in Toronto, with expansion to U.S. clinical sites later this year. Article content About PQ203 Article content PQ203 is the company's first internally owned AI designed peptide therapeutic entering the clinic. PQ203 is a novel Peptide Drug Conjugate composed of a peptide targeting the Sortilin receptor conjugated to the cytotoxic agent monomethyl auristatin E. The Sortilin receptor is expressed in a high percentage of diseased tissue from Triple Negative Breast Cancer (TNBC) patients and as such represents a novel target for this challenging sub-type of breast cancer. ProteinQure has generated data that PQ203 exhibits potent efficacy in multiple patient-derived xenograft (PDX) models including those resistant to Sacituzumab Govitecan (Trodelvy™), an antibody drug conjugate that is the emerging standard of care for metastatic TNBC. Article content Article content Article content
